Table 4.
Reactivity of antigens with 5 recurrent and 5 non-recurrent ovarian cancer patients (training set) and an independent recurrent ovarian patient population (test set, n=21)
| Sample-BSID | Sample | RecurInterval (T2) | Reactivity of Antigen Biomarkers | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Training Set | Training Set | CA125 | HARS | 4B7 | 4H4 | 5H6 | Ro52 | CDR2 | T71-2a | ||
|
| |||||||||||
| 674 | P128-Cancer(R)-T2 | −8.70 | 13 | 0.1 | 0.21 | ||||||
|
|
|||||||||||
| 1740 | P135-Cancer(R)-T2 | −16.30 | 11 | 15.15 | 1.75 | ||||||
|
|
|||||||||||
| 1681 | P146-Cancer(R)-T2 | −8.20 | 25 | 0.09 | 0.45 | ||||||
|
|
|||||||||||
| 3905 | P184-Cancer(R)-T2 | −14.30 | 5 | 0.2 | |||||||
|
|
|||||||||||
| 3776 | P175-Cancer(R)-T2 | −9.50 | 18 | 0.09 | 0.13 | 34.5 | 0.3 | 0.06 | |||
|
|
|||||||||||
| 784 | P25-Cancer(NR)-T2 | 12 | 0.1 | ||||||||
|
|
|||||||||||
| 832 | P164-Cancer(NR)-T2 | 28 | |||||||||
|
|
|||||||||||
| 4012 | P189-Cancer(NR)-T2 | 6 | 0.07 | 1.93 | 0.29 | ||||||
|
|
|||||||||||
| 4069 | P206-Cancer(NR)-T2 | 7 | |||||||||
|
|
|||||||||||
| 7428 | P281-Cancer(NR)-T2 | 6 | 0.06 | 0.07 | 0.04 | ||||||
|
| |||||||||||
| Test Set | Test Set | CA125 | HARS | 4B7 | 4H4 | 5H6 | Ro52 | CDR2 | T71-2a* | Number of Antigens reacting with each patient | |
|
| |||||||||||
| 1667 | P178-Cancer(R)-T2 | −4.20 | 203 | 0.04 | 0.04 | 0.04 | 1.65 | 4 | |||
|
|
|||||||||||
| 4694 | P265-Cancer(R)-T2 | −4.87 | 54 | 0.09 | 0.06 | 0.04 | 0.04 | 1.06 | 5 | ||
|
|
|||||||||||
| 7183 | P295-Cancer(R)-T2 | −5.77 | 18 | 0.22 | 0.21 | 2 | |||||
|
|
|||||||||||
| 5110 | P283 -Cancer(R)-T2 | −13.60 | 22 | 0.05 | 1.82 | 2 | |||||
|
|
|||||||||||
| 11499 | P300-Cancer(R)-T2 | −3.73 | 12 | 0.05 | 0.21 | 0.34 | 3 | ||||
|
|
|||||||||||
| 12898 | P326*-Cancer(R)-T2 | −4.30 | 41 | 0.04 | 1.49 | 0.81 | 3 | ||||
|
|
|||||||||||
| 12912 | P336-Cancer(R)-T2 | −10.00 | 20 | 0 | |||||||
|
|
|||||||||||
| 12897 | P341-Cancer(R)-T2 | −7.10 | 37 | 0.04 | 1.45 | 2 | |||||
|
|
|||||||||||
| 12863 | P342-Cancer(R)-T2 | −3.30 | 5 | 0.04 | 1 | ||||||
|
|
|||||||||||
| 12920 | P356*-Cancer(R)-T2 | −9.07 | 11 | 0 | |||||||
|
|
|||||||||||
| 14698 | P367*-Cancer(R)-T2 | −4.33 | 29 | 1.34 | 4.93 | 0.37 | 3 | ||||
|
|
|||||||||||
| 14697 | P370-Cancer(R)-T2 | −2.63 | 13 | 0.11 | 10.24 | 0.32 | 3 | ||||
|
|
|||||||||||
| 15178 | P386-Cancer(R)-T2 | −17.27 | 16 | 0.25 | 0.5 | 2 | |||||
|
|
|||||||||||
| 15256 | P392-Cancer(R)-T2 | −5.93 | 9 | 0.06 | 0.38 | 2 | |||||
|
|
|||||||||||
| 15264 | P376-Cancer(R)-T2 | −9.93 | 7 | 0.04 | 0.38 | 0.51 | 3 | ||||
|
|
|||||||||||
| 15180 | P378-Cancer(R)-T2 | −12.37 | 9 | 0.22 | 1 | ||||||
|
|
|||||||||||
| 15259 | P393*-Cancer(R)-T2 | −5.03 | 26 | 0.09 | 0.55 | 2 | |||||
|
|
|||||||||||
| 15266 | P398*-Cancer(R)-T2 | −10.30 | 24 | 0.04 | 1.14 | 2 | |||||
|
|
|||||||||||
| 15274 | P400-Cancer(R)-T2 | −4.50 | 6 | 0.21 | 1 | ||||||
|
|
|||||||||||
| 15776 | P410-Cancer(R)-T2 | −3.23 | 24 | 0.07 | 0.2 | 0.2 | 0.12 | 20.21 | 0.36 | 0.06 | 6 |
|
|
|||||||||||
| 15770 | P413-Cancer(R)-T2 | −15.53 | 8 | 0.37 | 1.05 | 2 | |||||
Note: The sero reactivity of the recombinant antigen biomarkers revealed 3 different range of affinity toward serum IgGs such as strong (>10 fold above the cut off, dark blue shade); moderate ((2–10) above the cutoff, medium blue shade) and weak (< 2 fold above the cutoff, light blue shade)
Ovarian cancer patients with asterisk had evidence of disease months before the clinical recurrence ; NED: No evidence of disease; EOD: Evidence of disease.
R represents recurrent ovarian cancer patients; NR represents non-recurrent ovarian cancer patients
T2 represents time in months before the clinical recurrence
Cutoff for HARS, 4B7, 4H4, 5H6: 0.03
Cutoff for Ro52 and CDR2 : 0.17
For calculation of cutoffs, please see Materials and Methods, Table 2
T7 1-2a has been dropped out in the Test set because it reacted with 4.8% of the sample population in the test set, so it was never considered in further analyses in the test set. The antigens that showed sensitivity >10% in the test set were only selected for further analyses.